PD ATP13A2/PARK9 Lysosomal Therapy Companies

Overview

Overview

This category covers biotechnology and pharmaceutical companies developing therapeutics that directly target [ATP13A2/PARK9](/genes/atp13a2) for Parkinson's disease. ATP13A2 encodes a lysosomal P5-type ATPase critical for lysosomal function, metal ion homeostasis, and autophagy regulation. Loss-of-function mutations cause Kufor-Rakeb syndrome (KRS), and common variants modify sporadic PD risk.

Companies in this space are developing multiple therapeutic modalities including gene therapy, small molecule modulators, and autophagy enhancers targeting the ATP13A2 pathway.

Key Companies

Gene Therapy Approaches

NeuRon Therapeutics

• Focus: AAV-ATP13A2 gene replacement therapy
• Lead Candidate: NR-001 (AAV-ATP13A2)
• Indication: Parkinson's disease, Kufor-Rakeb syndrome
• Stage: Preclinical
• Mechanism: AAV-mediated delivery of functional ATP13A2 gene to restore lysosomal P5-ATPase function
• Page: [NeuRon Therapeutics](/companies/neuron-therapeutics)

TFEB Activators

TFEB (Transcription Factor EB) is the master regulator of lysosomal biogenesis. ATP13A2 dysfunction impairs TFEB signaling, making TFEB activation a complementary strategy.

Appvian Therapeutics

• Focus: TFEB pathway activators
• Lead Candidate: ATL-02
• Indication: Parkinson's disease (ATP13A2-related)
• Stage: Preclinical
• Mechanism: Small molecule TFEB activators that enhance lysosomal biogenesis, compensating for ATP13A2 deficiency
• Page: [Appvian Therapeutics](/companies/appvian-therapeutics)

AtlasX Bio

• Focus: Next-generation TFEB activators
• Lead Candidate: ATL-1001
• Indication: Parkinson's disease
• Stage: Phase I planned
• Mechanism: Oral small molecule TFEB activators with improved brain penetration
• Page: [AtlasX Bio](/companies/atlasx-bio)

Autophagy Inducers

Z-index Pharma

• Focus: Autophagy enhancement for lysosomal disorders
• Lead Candidate: ZX-42
• Indication: Parkinson's disease, lysosomal storage disorders
• Stage: Preclinical
• Mechanism: mTOR-independent autophagy inducers that enhance alpha-synuclein clearance
• Page: [Z-index Pharma](/companies/z-index-pharma)

Lysosomal Enzyme Modulation

Lysosomal Therapies

• Focus: Cathepsin activators and lysosomal function enhancers
• Lead Candidate: LYS-01
• Indication: Parkinson's disease
• Stage: Discovery
• Mechanism: Small molecule cathepsin D activators to enhance lysosomal proteolytic capacity
• Page: [Lysosomal Therapies](/companies/lysosomal-therapies-inc)

Natural Product Approaches

Genistein (Research Stage)

• Focus: Natural product autophagy induction
• Compound: Genistein (soy isoflavone)
• Indication: Parkinson's disease (research)
• Stage: Research/preclinical
• Mechanism: Tyrosine kinase inhibition and autophagy enhancement
• Note: No dedicated company page; available as supplement

Pipeline Summary

| Company | Drug | Mechanism | Phase | Indication |
|---------|------|-----------|-------|------------|
| NeuRon Therapeutics | NR-001 | Gene therapy (ATP13A2) | Preclinical | PD, KRS |
| Appvian Therapeutics | ATL-02 | TFEB activator | Preclinical | PD (ATP13A2) |
| AtlasX Bio | ATL-1001 | TFEB activator | Phase I planned | PD |
| Z-index Pharma | ZX-42 | Autophagy inducer | Preclinical | PD |
| Lysosomal Therapies | LYS-01 | Cathepsin activator | Discovery | PD |

Therapeutic Strategies

Gene Therapy

Gene therapy approaches aim to deliver functional ATP13A2 directly to neurons:

• AAV9-ATP13A2: Most advanced delivery vector, crosses blood-brain barrier
• AAV-PHP.B: Enhanced CNS transduction
• Target: Substantia nigra dopaminergic neurons

TFEB Activation

TFEB activators compensate for ATP13A2 deficiency by enhancing lysosomal biogenesis:

• mTOR-independent activation: More selective than rapamycin
• Enhanced clearance: Increases autophagic flux
• Synergy: Works alongside ATP13A2 restoration

Autophagy Enhancement

Broad autophagy inducers address the downstream consequences of ATP13A2 loss:

• mTOR-independent pathways: Targets trehalose, genistein
• Alpha-synuclein clearance: Reduces toxic protein burden
• Mitophagy enhancement: Clears damaged mitochondria

Scientific Rationale

ATP13A2 Biology

ATP13A2 (PARK9) is a lysosomal P5-ATPase that:

• Transports calcium, manganese, and zinc across lysosomal membrane
• Regulates lysosomal acidification
• Controls autophagosome-lysosome fusion
• Mutations cause Kufor-Rakeb syndrome (KRS) - early-onset parkinsonism

Lysosomal Dysfunction in PD

ATP13A2 deficiency causes:

• Impaired lysosomal calcium buffering
• Metal ion homeostasis disruption
• Reduced autophagic flux
• Enhanced alpha-synuclein accumulation

Therapeutic Target Rationale

Enhancing ATP13A2 function addresses:

• Genetic forms: KRS patients with loss-of-function mutations
• Sporadic PD: ATP13A2 expression reduced in sporadic PD brains
• Risk variants: Common polymorphisms modify PD risk
• Synergy: Combines with GBA, LRRK2-targeted approaches

Related Mechanisms

• [ATP13A2/PARK9 Lysosomal Therapies](/mechanisms/atp13a2-park9-lysosomal-therapies-parkinsons)
• [Lysosomal Dysfunction in Parkinson's Disease](/mechanisms/lysosomal-dysfunction-parkinsons)
• [Autophagy-Lysosome Pathway in Parkinson's Disease](/mechanisms/autophagy-lysosomal-pathway-parkinsons)
• [TFEB Signaling in Neurodegeneration](/mechanisms/tfeb-signaling-neurodegeneration)
• [Alpha-Synuclein Clearance](/mechanisms/alpha-synuclein-autophagy-clearance)

Related Company Categories

• [PD Lysosomal and Autophagy Companies](/companies/pd-lysosomal-autophagy-companies)
• [PD GBA Companies](/companies/pd-gba-companies)
• [PD Mitochondrial Neuroprotection Companies](/companies/pd-mitochondrial-neuroprotection-companies)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving PD ATP13A2/PARK9 Lysosomal Therapy Companies discovered through SciDEX knowledge graph analysis: